Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2013 Oct:24 Suppl 6:vi138-43. doi: 10.1093/annonc/mdt320. Epub 2013 Aug 22.

Authors

M F Fey¹, C Buske; ESMO Guidelines Working Group

Affiliation

¹ Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland.

PMID: 23970018
DOI: 10.1093/annonc/mdt320

No abstract available

Publication types

Practice Guideline

MeSH terms

Adult
Aging
Antineoplastic Agents / therapeutic use
CCAAT-Enhancer-Binding Proteins / genetics
Europe / epidemiology
Follow-Up Studies
Humans
Leukemia, Promyelocytic, Acute / diagnosis*
Leukemia, Promyelocytic, Acute / epidemiology
Leukemia, Promyelocytic, Acute / therapy*
Nuclear Proteins / genetics
Nucleophosmin
Risk Assessment
Translocation, Genetic / genetics
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics

Substances

Antineoplastic Agents
CCAAT-Enhancer-Binding Proteins
CEBPA protein, human
Nuclear Proteins
Nucleophosmin
FLT3 protein, human
fms-Like Tyrosine Kinase 3